Calypso Medical Technologies, Inc., announced that The Royal Marsden in London is the first cancer center in the United Kingdom to offer the Calypso System to provide accurate, precise, real-time tumor tracking for patients undergoing external beam radiation therapy for prostate cancer.

The Calypso System, with its GPS for the Body utilizes miniature implanted Beacon transponders to provide precise, continuous information on the location of the tumor during external beam radiation therapy. Any movement by the patient, including internal movement of the tumor, may cause the radiation to miss its intended target and hit adjacent healthy tissue. In contrast to other tumor targeting solutions, the Calypso System provides real-time tumor position information, thereby allowing physicians to deliver radiation directly to the tumor while sparing the surrounding healthy organs from exposure.

“The Calypso System strengthens our state-of-the-art treatment and bolsters our ability to deliver the best care to patients,” said Professor David Dearnaley, M.D., Professor of Uro-Oncology and Honorary Consultant Clinical Oncologist at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. “This innovative technology provides objective guidance for managing organ motion, which will enable our clinicians to ensure that radiation is delivered directly to the tumor site. This will reduce the dose to surrounding healthy tissue, which has been shown in our clinical practice to result in fewer and less severe side effects. In addition to the prostate, we are excited about applying the Calypso System to research additional body sites, such as the lung, where tumor motion makes treatment very challenging.”

“We are proud to join forces with The Royal Marsden to ensure accurate delivery of radiation for prostate cancer and to enhance patient care,” said Eric Meier, President and Chief Executive Officer at Calypso Medical Technologies. “This installation extends the availability of the Calypso System into the United Kingdom and expands our distribution of the Calypso System in Europe. More than 5,000 patients have already been treated with the Calypso System and this latest international expansion will help even more patients receive the benefits of GPS for the Body technology to guide their cancer radiation therapy treatments. In fact, a recent clinical study demonstrated that the Calypso System enabled planning target volume (PTV) margin reduction which resulted in improved outcomes for patients.¹”

Source: Calypso Medical Technologies